GHK-Cu
A naturally occurring copper-binding tripeptide with the strongest cosmetic-skin evidence record of any peptide, driving collagen synthesis, wound healing, and broad gene-expression effects.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, first isolated from human plasma by Loren Pickart in 1973. It acts as both a copper shuttle for enzymes like lysyl oxidase and superoxide dismutase and a signaling molecule that modulates the expression of over 4,000 genes tied to healing, aging, and regeneration. Topical GHK-Cu has 40+ years of cosmetic use and human data for collagen, firmness, and wrinkle reduction, while injectable use remains research-use-only with no completed human trials. Endogenous plasma GHK declines from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60, which underpins much of the interest in supplementation.
Class
Copper-complexed tripeptide (Gly-His-Lys + Cu²⁺)
Half-life
~30-60 minutes in plasma (approximate legacy figure; no robust modern human PK study). Tissue-level gene-expression effects persist 12-24+ hours.
Routes
Topical, Subcutaneous, Microneedling, Intravenous (research)
Category
Skin, Hair & Cosmetic
Researched benefits
What it's studied for
Collagen and elastin synthesis
Stimulates type I collagen production in human dermal fibroblasts at low nanomolar-to-picomolar concentrations and increases elastin, supplying copper to lysyl oxidase for collagen crosslinking. Human topical trials show 15-25% improvements in firmness metrics.
Wound healing and tissue remodeling
Accelerates wound closure by chemoattracting macrophages, mast cells, and capillary cells to injury sites and increasing glycosaminoglycans (dermatan/chondroitin sulfate) and decorin. Animal models show 30-50% faster closure; a human post-CO2-laser trial showed ~25% faster epithelial recovery.
Anti-aging skin appearance
Consistent human topical evidence over 8-16 weeks for reduced fine lines, improved texture and firmness, increased skin thickness, and reduced photodamage. Effects are cumulative and modest relative to ablative procedures but reproducible across independent research groups.
Antioxidant and anti-inflammatory activity
Acts as a copper regulator supporting superoxide dismutase and downregulates pro-inflammatory signaling. In a zebrafish model it attenuated CuSO4- and LPS-induced inflammation via the JAK1 pathway, reducing immune-cell migration and cytokine expression.
Hair follicle support
Stimulates bulge-region stem cell activity, promotes VEGF-driven angiogenesis to follicles, and prolongs the anagen phase. Mouse studies place it near minoxidil-level activity; one human 0.02% lotion trial showed a ~7% hair-count increase at 16 weeks.
Broad gene-expression modulation
Genomic and Connectivity Map analyses show GHK-Cu modulates expression of over 4,000 human genes, including DNA-repair, antioxidant, and anti-inflammatory pathways, resetting expression toward a healthier, younger tissue signature in cell-based studies.
Matrix metalloproteinase regulation
Stimulates wound-healing MMPs while suppressing MMPs that degrade healthy tissue, and helped correct the MMP-9/TIMP-1 imbalance in a smoke-induced emphysema model, contributing to balanced extracellular matrix turnover.
Mechanism
How it works
GHK-Cu works through two intertwined roles in a single molecule: a copper carrier function and a gene-signaling function. It binds copper(II) with high affinity (log K around 16.4, close to albumin's 16.2) and can supply or regulate copper for copper-dependent enzymes including lysyl oxidase (collagen crosslinking), superoxide dismutase (SOD1, antioxidant defense), cytochrome c oxidase, and tyrosinase. This copper delivery underlies its characteristic blue-to-blue-green color, which reflects proper copper(II) chelation.
As a signaling peptide, GHK-Cu directly stimulates dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans, and decorin, driving extracellular matrix remodeling and wound contraction. It also modulates matrix metalloproteinases and their inhibitors — stimulating wound-healing MMPs while suppressing those that break down healthy tissue — and chemoattracts macrophages, mast cells, and capillary cells to sites of injury to coordinate repair.
At the transcriptomic level, Connectivity Map and genomic analyses have identified GHK-Cu as a modulator of more than 4,000 human genes, including networks governing antioxidant defenses, DNA repair, and anti-inflammatory pathways. This broad gene-expression reset toward a regenerative signature is the basis for its studied roles in aging, though clinical translation from cell lines to intact human tissue remains cosmetic-scale rather than proof of systemic gene rewriting.
Endogenous GHK circulates in plasma at roughly 200 ng/mL in young adults and falls to about 80 ng/mL by age 60. This age-related decline, combined with the peptide's collagen, antioxidant, and gene-expression activity, forms the rationale for supplemental GHK-Cu in tissue-maintenance and longevity research contexts.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Injectable vials are reconstituted with bacteriostatic water. Example: a 50 mg vial plus 2 mL BAC water yields 25 mg/mL, so 250 mcg = 0.01 mL (1 unit on a U-100 insulin syringe) and 500 mcg = 0.02 mL (2 units). Keep the reconstituted vial refrigerated. Topical GHK-Cu is sold as pre-made serums and creams (typically 1-5%); for microneedling a sterile solution is used.
Topical (evidence-backed)
- Dose
- 1-5% concentration in serum or cream (commonly 1-3%)
- Frequency
- 1-2x daily
- Timing
- Applied to cleansed skin; avoid same-session layering with strong acids, retinoids, or high-dose vitamin C
- Duration
- Ongoing; visible texture/firmness changes over 8-12+ weeks
- Route
- Topical
The route with real human cosmetic data. Benefits fade if discontinued. Formulation and skin penetration matter as much as the concentration on the label.
Beginner (injectable, RUO)
- Dose
- 1 mg (or 200-500 mcg) subcutaneous
- Frequency
- Once daily
- Timing
- Some run 5 days on / 2 days off
- Duration
- 4-6 weeks
- Route
- Subcutaneous
No clinically established injectable dose exists. Community protocols only. Can be combined with topical application for skin-specific goals.
Intermediate (injectable, RUO)
- Dose
- 2 mg subcutaneous
- Frequency
- Once daily
- Timing
- Daily
- Duration
- 8 weeks
- Route
- Subcutaneous
Often combined with topical application for enhanced skin effects. Rotate injection sites to reduce burning; supplementing zinc frequently reduces injection-site reactions.
Advanced (injectable, RUO)
- Dose
- 2-4 mg subcutaneous
- Frequency
- Once daily
- Timing
- Daily
- Duration
- 8-12 week cycles followed by 4-6 week off-period
- Route
- Subcutaneous
Stacked with BPC-157 and/or TB-500 for comprehensive tissue remodeling, plus topical for facial goals. Off-cycling is used as a precaution against theoretical copper accumulation.
- No human clinical trial has established a definitive injectable dosing protocol for GHK-Cu; all injectable regimens are research-use-only community practice.
- Topical delivery is the route with genuine human evidence and the cleanest safety record — for evidence-backed use, topical is preferred.
- Injectable use bypasses the gut's copper regulation, so cycling (4-8 weeks on, 4-6 weeks off) is used to limit theoretical copper accumulation.
- Because GHK-Cu raises zinc demand, monitor for low-zinc signs (acne, cracked mouth corners, sore tongue, hair shedding) and consider a zinc/copper/ceruloplasmin panel with added zinc.
- Independent testing has found vials 30-95% underdosed; test material for dose accuracy and heavy metals and buy from vendors who publish COAs.
- Diluting more generously and letting the solution reach room temperature reduces injection sting.
Evidence
Research & clinical studies (9)
Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
In this randomized controlled trial (n=13), patients using GHK-Cu skincare after CO2 laser resurfacing reported significantly higher satisfaction with skin-quality improvement, though objective erythema resolution did not differ significantly from controls.
PMID 16847171GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Summarizes evidence that GHK-Cu stimulates collagen and glycosaminoglycan synthesis, modulates tissue-remodeling enzymes, and activates immune and repair pathways, with cosmetic studies reporting improved elasticity, firmness, and reduced fine lines and photodamage.
PMID 26236730The human tri-peptide GHK and tissue remodeling
Reviews evidence that GHK-Cu activates tissue-remodeling mechanisms including collagen and elastin synthesis, anti-inflammatory signaling, and growth-factor upregulation, with controlled studies showing improved skin elasticity and firmness.
PMID 18644225Regenerative and Protective Actions of the GHK-Cu Peptide
Pickart & Margolina review GHK-Cu's copper-dependent collagen synthesis, antioxidant gene activation, and regenerative and protective actions across skin and other tissues.
Glycyl-L-histidyl-L-lysine-Cu2+ (GHK-Cu) attenuates CuSO4- or LPS-induced inflammation in a zebrafish larvae model
GHK-Cu reduced immune-cell migration and pro-inflammatory cytokine expression while enhancing antioxidant defenses, with anti-inflammatory effects associated with downregulation of the JAK1 signaling pathway.
PMID 41997403The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways
GHK-Cu extended lifespan and reduced aging-related decline in C. elegans by improving mitochondrial energy production, reducing oxidative stress, and upregulating protective genes via the DAF-16 and SKN-1 stress-response pathways.
PMID 42084774Microenvironment-responsive injectable dynamic hydrogel for sequential antioxidant and tissue regeneration therapy of radiation-induced skin injury
A GHK-Cu-containing dynamic hydrogel accelerated healing of radiation-induced skin injury by first neutralizing reactive oxygen species then sustaining GHK-Cu release for anti-inflammatory and collagen-building repair in lab and animal models.
PMID 42058630Hierarchical regulation and mechanism of open-hollow-fibrous network structures: osteogenic-angiogenic coupling responses of poly(γ-benzyl-L-glutamate) microspheres
GHK-Cu-functionalized nanofibrous microspheres enhanced both bone-cell mineralization and blood-vessel formation, increasing osteogenic gene-expression markers 1.61- to 3.53-fold over non-functionalized controls.
PMID 42320090Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs
GHK-Cu produced behavioral rescue in middle-aged mice, but hippocampal aging programs diverged depending on whether it was delivered intraperitoneally or intranasally.
PMID 42245779Combinations
Stacking & blends
BPC-157 + GHK-Cu: Wound Healing & Skin Repair
Wound healing and skin regeneration
BPC-157 accelerates deep tissue, tendon, and vascular healing and angiogenesis, while GHK-Cu stimulates fibroblast activity, antioxidant gene expression, and extracellular matrix renewal — addressing both deep structural integrity and surface skin quality through distinct mechanisms.
GHK-Cu + Argireline: Skin Rejuvenation & Line Reduction
Facial anti-aging and expression-line reduction
GHK-Cu drives collagen/elastin synthesis and skin remodeling, while Argireline (acetyl hexapeptide-3) inhibits neurotransmitter-mediated facial muscle contraction — combining complementary structural and neuromuscular anti-aging pathways.
GHK-Cu + Epithalon: Anti-Aging
Longevity and tissue rejuvenation
GHK-Cu activates antioxidant and anti-inflammatory gene networks for tissue rejuvenation, while Epithalon is studied for telomerase stimulation and pineal/circadian regulation — addressing aging at both cellular-replication and tissue-maintenance levels.
GLOW Blend
Synergistic tissue repair and skin quality
A research blend combining GHK-Cu's collagen synthesis and dermal remodeling with BPC-157's systemic tissue repair and TB-500's soft-tissue regeneration for broad wound-healing and skin effects.
Hair regrowth topical stack
Androgenetic alopecia and diffuse thinning
GHK-Cu addresses the collagen, vascular, and follicle-support aspects of hair maintenance via VEGF-driven angiogenesis and anagen prolongation, complementing minoxidil, which does not directly target those pathways; finasteride or RU-58841 are sometimes added.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Wilson's disease and other copper-metabolism disorders (GHK-Cu binds and delivers copper)
- Pregnancy and breastfeeding (no systemic safety data; copper handling shifts in pregnancy)
- Known allergy/contact dermatitis to copper-peptide products
Topical GHK-Cu has an extensive multi-decade cosmetic safety record with rare contact dermatitis as the main concern and no serious adverse events reported. Injectable use has no completed human trials; its main added concern is theoretical copper accumulation because subcutaneous delivery bypasses gut copper regulation — monitor serum copper, ceruloplasmin, and zinc balance, and use cycling. Supplementing zinc frequently reduces injection-site reactions. Because vials are often underdosed, testing for dose accuracy and heavy metals is advised.
FAQ
GHK-Cu — common questions
What is GHK-Cu?
GHK-Cu is the copper(II) complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine, first isolated from human plasma by Loren Pickart in 1973. It acts as both a copper carrier and a signaling peptide, and is one of the most extensively studied peptides for skin health, wound healing, and collagen synthesis.
Why is GHK-Cu blue?
The characteristic blue-to-blue-green color comes from the copper(II) chelation complex — the GHK tripeptide forms a coordination complex with Cu²⁺ ions. This coloration is normal and expected; a colorless or off-white solution may indicate inadequate copper incorporation, and the same copper binding drives GHK-Cu's collagen and antioxidant activity.
Is injectable GHK-Cu clinically proven?
No. There are no completed human clinical trials of injectable GHK-Cu and no established dose — all subcutaneous use is research-use-only community practice. The genuine human evidence for GHK-Cu is topical (cosmetic anti-aging and post-procedure healing), not injected.
What is the difference between topical and injectable GHK-Cu?
Topical GHK-Cu is a mainstream cosmetic ingredient (INCI: Copper tripeptide-1) with real human data, typically at 1-3% in serums and creams applied once or twice daily. Injectable use has no trials, no approved dose, and adds a copper-load concern because injection bypasses the gut's copper regulation. The evidence-backed route is topical.
Should I worry about copper overload?
It is a legitimate theoretical concern for injectable use specifically, since subcutaneous dosing skips the gut's tight copper regulation. Community protocols run 4-8 week cycles with 4-6 week off-periods to limit accumulation. Topical use does not carry the same systemic load, and anyone with a copper-metabolism disorder should avoid GHK-Cu entirely.
Does GHK-Cu help with hair loss?
Research shows GHK-Cu stimulates follicle stem cells, promotes VEGF-driven angiogenesis, and prolongs the anagen phase. Mouse studies place it near minoxidil-level activity, and one human trial with a 0.02% lotion showed about a 7% hair-count increase at 16 weeks. It is often combined with minoxidil in scalp formulations to address the vascular and collagen aspects minoxidil does not target.
How long until I see results?
For topical use, most reported changes in texture and firmness appear over 8-12+ weeks of consistent daily application, and benefits fade if you stop. For injectable use there is no reliable timeline because there is no clinical data; any reported effects are anecdotal and unverified.
Is GHK-Cu FDA approved?
No. GHK-Cu has no FDA drug approval. Topical GHK-Cu is a permitted cosmetic ingredient sold OTC. Injectable GHK-Cu was removed from the FDA 503A Category 2 bulk-substances list in April 2026 and is scheduled for Pharmacy Compounding Advisory Committee review anticipated before February 2027; it is otherwise sold as a research chemical and not approved for human consumption.
